Skip to main content
. 2023 Sep 11;16:17562848231197923. doi: 10.1177/17562848231197923

Figure 5.

Figure 5.

Cumulative incidence of infliximab discontinuation due to unwanted response, the dashed vertical line at 11.2 months indicates the moment of lines crossing.